002868 Lifecome Biochemistry
- 16.62
- +0.62+3.88%
Lifecome Biochemistry News
Lukang Biochemical (002868.SZ): Net loss of 31.3428 million yuan in the first quarter
Gelonghui, April 30, 丨 Lukang Biochemical (002868.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 160 million yuan, up 60.09% year on year; net profit attributable to shareholders of listed companies was 31.3428 million yuan, an increase in year-on-year losses; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - RMB 32.2093 million; and basic earnings per share - 0.2 yuan.
Lukang Biochemical (002868.SZ): The natamycin series products produced are mainly used for food preservation and preservation
Gelonghui March 26 | Lukang Biochemical (002868.SZ) said on the investor interactive platform that the natamycin series products produced by the company are mainly used for food preservation and preservation, and can be used in cheese, bread and pastries, braised meat products, fried meat, salad dressing, etc.
Lukang Biochemical (002868.SZ) plans to sell part of its assets located in Pudan Biological Professional Park to Putan Thermal Energy for 67.5 million yuan
Zhitong Finance App News, Lukang Biochemical (002868.SZ) announced that the company intends to sell some equipment fixed assets, building fixed assets and state-owned land use rights located in the Pudan Biological Professional Park in Pucheng County, Fujian Province. The transaction price is 67.5 million yuan (tax included). The details of this transaction are some equipment fixed assets, building-type fixed assets and state-owned land use rights located in Putan Biological Professional Park in Pucheng County, Fujian Province. Among them, there are 5 housing buildings, which are comprehensive housing, temporary storage workshops for sludge dehydration and drying, pharmacies, and hazardous waste
Lukang Biochemical (002868.SZ): Pre-loss of 210 million yuan to 230 million yuan in 2023
Gelonghui, January 29丨Lukang Biochemical (002868.SZ) announced the 2023 annual results forecast, with operating income of 51 million yuan to 520 million yuan; net profit loss attributable to shareholders of listed companies of 21 million yuan to 230 million yuan, loss of 121.94 million yuan in the same period last year; net profit loss after deducting non-recurring profit and loss of 225 million yuan to 250 million yuan; loss of 123.21 million yuan for the same period last year; basic earnings loss per share of 1.35 yuan/share — 1.48 yuan/share. During the reporting period, the company's operating income compared to the same period last year
The A-share photovoltaic sector fluctuated and weakened, and Lukang Biochemical fell to a standstill
Gelonghui, January 17 | Lukang Biochemical fell to a halt. Qingyuan Co., Ltd., Zhonghi New Materials, Dike Co., Ltd., Ruihe shares, and Elken Technology fell more than 5%.
The photovoltaic sector continues to be active, Lukang Biochemical 4 connected panels
Gelonghui, January 16 | Lukang Biochemical 4 times in a row. Yaopi Glass and Ancai Hi-Tech hit a rise or fall, while Cent Co., Ltd., Sanbian Technology, and Conch New Materials increased ahead. According to the news, according to InfoLink Consulting data, as of the end of December 2023, the PERC battery production capacity had reached 50.6 GW of projects that had been decided to shutdown/stop production; the scale of the TopCon project facing suspended production expansion reached 132 GW, and the scale of delayed production capacity was quite large. If the industry continues to lose money, the rate at which production capacity is being cleared will gradually accelerate.
Lukang Biochemical (002868.SZ): Some supervisors and executives plan to reduce their holdings by no more than 161,000 shares
Gelonghui, January 12 | Lukang Biochemical (002868.SZ) announced that shareholder Feng Zhenwu directly held 115,725 shares of the company (0.07% of the company's total share capital) to reduce his holdings of the company's shares by no more than 28,931 shares (0.019% of the company's total share capital) through centralized bidding transactions (excluding the period where holdings reduction is prohibited according to relevant laws and regulations) within 3 months after the announcement of the capital reduction plan. Shareholder Lou Lijun directly held 55,282 shares of the company (accounting for 0.04% of the company's total share capital) and traded 15 shares since the date of the announcement of the capital reduction plan
Lukang Biochemical (002868.SZ): Proposed establishment of a wholly-owned subsidiary Lukang Import & Export
Gelonghui November 20 | Lukang Biochemical (002868.SZ) announced that on November 20, 2023, the company held the 35th (interim) meeting of the fourth board of directors to deliberate and pass the “Proposal on the Establishment of Wholly-owned Subsidiaries for Foreign Investment”. Based on strategic planning and future business development needs, the company plans to invest in the establishment of a wholly-owned subsidiary, Lukang Xinneng (Shanghai) Import and Export Co., Ltd. (“Lukang Import and Export” for short, the provisional name, subject to industrial and commercial registration). The company invests in its own capital and other means, with a registered capital of 10 million yuan, and holds 100% of Lukang's shares in import and export.
[Instant Analysis of BT Financial Report] Lukang Biochemical's 2023 Interim Report: Revenue Increased by 59.46%, PV Film Business Boosts Performance Growth
Lukang Biochemical (stock code: 002868) is a high-tech enterprise focusing on R&D, production and sales of veterinary drugs. In the 2023 interim report, the company achieved operating income of 230,041,548.11 yuan, an increase of 59.46% over the previous year. This is mainly due to the company's successful acquisition of Jiangxi Weike New Material Technology Co., Ltd., and invested in the establishment of Lukang (Haining) Adhesive Film Material Co., Ltd. to enter the photovoltaic film industry, forming a development model for the dual main business of “mobile protection products+photovoltaic film products”. As can be seen from the financial data, the company's operating costs increased by 55.92% year-on-year, mainly
Lukang Biochemical (002868SZ) related supervisors and executives reduced their holdings by a total of 53,600 shares
According to the Zhitong Finance App, Lukang Biochemical (002868.SZ) issued an announcement. As of the disclosure date of this announcement, the relevant supervisors and executives Feng Zhenwu, Li Junhui, Huang Hui, and Bao Zhongshou have implemented the holdings reduction plan. The above personnel have now reduced their holdings by a total of 53,600 shares.
Lifecome Biochemistry Resumes Factory Operations
02:08 AM EST, 02/07/2023 (MT Newswires) -- Lifecome Biochemistry (SHE:002868) resumed operations at its Putan veterinary drug factory yesterday. The Chinese biopharmaceutical company temporarily suspe
Express News | The opening of the POE film sector is active, Maohua Shihua Lianglian
Express News | The photovoltaic sector continues to rise, leading the way in the direction of auxiliary materials
Express News | Evaluation of A-shares: The Shanghai Index fluctuated narrowly to adjust the turnover of the two markets to fall below 600 billion dollars
Lifecome Biochemistry Nixes Plan to Buy New Materials, Thermal Energy Firms
08:23 PM EDT, 08/07/2022 (MT Newswires) -- Lifecome Biochemistry (SHE:002868) cancelled its plan to buy the entire equity stakes in two companies, it said Monday. The Chinese pharmaceutical company ha
Lukang biochemical (002868.SZ): "Putan Industrial Park cogeneration project" unit start-up and grid-connected trial operation
Zhitong Financial APP News, Lukang biochemical (002868.SZ) notice, the company with its own funds to invest in the construction of the "Putan Industrial Park cogeneration project" ("cogeneration project") recently entered the unit start-up and grid trial operation stage. It is reported that the cogeneration project is located in Putan Industrial Park, Pucheng County, with the construction of two 90t/h high-temperature and high-pressure circulating fluidized bed boilers and one 12MW coal-fired back pressure unit, as well as simultaneous construction of desulphurization, denitrification, dust removal equipment and supporting facilities.
002868.SZ has obtained "Veterinary Drug GMP Certificate" and "Veterinary Drug production license".
Zhitong Financial APP News, Lukang biochemical (002868.SZ) issued a notice that the company recently received the people's Republic of China "Veterinary Drug GMP Certificate" and "Veterinary Drug production license" issued by the Agricultural and Rural Department of Fujian Province. The Code for quality Management of Veterinary Drug production (revised in 2020) (referred to as "the new version of Veterinary Drug GMP") was issued on April 21, 2020 and will enter into force on June 1, 2020. The new version of veterinary drug GMP has more stringent requirements on the hardware and software of veterinary drug production, and requires to meet the requirements of the new version of veterinary drug GMP by June 1, 2022. According to the new version of veterinary drug GMP
Lukang biochemical (002868.SZ): director Lai Jianping intends to reduce his holdings of no more than 57900 shares
002868.SZ announced that director Lai Jianping directly holds 231660 shares of the company (accounting for 0.15% of the company's total share capital) and plans to reduce no more than 57915 shares of the company through centralized bidding (except for the period during which the reduction is prohibited according to relevant laws and regulations) within 6 months after the announcement of the reduction plan. That is, not more than 0.04% of the total share capital of the company.
Lai Jianping, director of 002868.SZ, intends to reduce his holdings of no more than 57900 shares.
Zhitong Financial APP News, Lukang biochemical (002868.SZ) announcement, company director Lai Jianping intends to reduce the company's shares, is expected to reduce no more than 57900 shares.
Lukang biochemical (002868.SZ): net loss of 8.9138 million yuan in the first quarter
002868.SZ released its report for the first quarter of 2022 on April 14. During the reporting period, the company realized operating income of 62.6871 million yuan, down 31.06% from the same period last year. The net profit belonging to shareholders of listed companies was-8.9138 million yuan, turning losses into profits compared with the same period last year. Net profits belonging to shareholders of listed companies after deducting non-recurring gains and losses were-4.9516 million yuan; and basic earnings per share were-0.06 yuan.
Analysis
Price Target
No Data
